Rein SM, Lodi S, Logan RW, Touloumi G, Antoniadou A, Wittkop L, Bonnet F, van Sighem A, van der Valk M, Reiss P, Klein MB, Young J, Jarrin I, d'Arminio Monforte A, Tavelli A, Meyer L, Tran L, Gill MJ, Lang R, Surial B, Haas AD, Justice AC, Rentsch CT, Phillips A, Sabin CA, Miro JM, Trickey A, Ingle SM, Sterne JAC, and Hernán MA
Background: A recent observational study suggested that the risk of cardiovascular events could be higher among antiretroviral therapy (ART)-naive individuals with HIV who receive integrase strand-transfer inhibitor (INSTI)-based ART than among those who receive other ART regimens. We aimed to emulate target trials separately in ART-naive and ART-experienced individuals with HIV to examine the effect of using INSTI-based regimens versus other ART regimens on the 4-year risk of cardiovascular events., Methods: We used routinely recorded clinical data from 12 cohorts that collected information on cardiovascular events, BMI, and blood pressure from two international consortia of cohorts of people with HIV from Europe and North America. For the target trial in individuals who had previously never used ART (ie, ART-naive), eligibility criteria were aged 18 years or older, a detectable HIV-RNA measurement while ART-naive (>50 copies per mL), and no history of a cardiovascular event or cancer. Eligibility criteria for the target trial in those with previous use of non-INSTI-based ART (ie, ART-experienced) were the same except that individuals had to have been on at least one non-INSTI-based ART regimen and be virally suppressed (≤50 copies per mL). We assessed eligibility for both trials for each person-month between January, 2013, and January, 2023, and assigned individuals to the treatment strategy that was compatible with their data. We estimated the standardised 4-year risks of cardiovascular events (myocardial infarction, stroke, or invasive cardiovascular procedure) via pooled logistic regression models adjusting for time and baseline covariates. In per-protocol analyses, we censored individuals if they deviated from their assigned treatment strategy for more than 2 months and weighted uncensored individuals by the inverse of their time-varying probability of remaining uncensored. The denominator of the weight was estimated via a pooled logistic model that included baseline and time-varying covariates., Findings: The analysis in ART-naive individuals included 10 767 INSTI initiators and 8292 non-initiators of INSTI. There were 43 cardiovascular events in INSTI initiators (median follow-up of 29 months; IQR 15-45) and 52 in non-initiators (39 months; 18-47): standardised 4-year risks were 0·76% (95% CI 0·51 to 1·04) in INSTI initiators and 0·75% (0·54 to 0·98) in non-INSTI initiators; risk ratio 1·01 (0·57 to 1·57); risk difference 0·0089% (-0·43 to 0·36). The analysis in ART-experienced individuals included 7875 INSTI initiators and 373 965 non-initiators. There were 56 events in INSTI initiators (median follow-up 18 months; IQR 9-29) and 3103 events (808 unique) in non-INSTI initiators (26 months; 15-37) in non-initiators: standardised 4-year risks 1·41% (95% CI 0·88 to 2·03) in INSTI initiators and 1·48% (1·28 to 1·71) in non-initiators; risk ratio 0·95 (0·60 to 1·36); risk difference -0·068% (-0·60 to 0·52)., Interpretation: We estimated that INSTI use did not result in a clinically meaningful increase of cardiovascular events in ART-naive and ART-experienced individuals with HIV., Funding: National Institute of Allergy and Infectious Diseases and National Institute on Alcohol Abuse and Alcoholism., Competing Interests: Declaration of interests SMR, RWL, and SMI report National Institutes of Health (NIH) grants paid to their institution during the conduct of the study. SL reports grants from the NIH and the Providence/Boston Center for AIDS Research. MAH reports grants from the NIH and personal honoraria from Cytel, ProPublica, and ADIA Lab. JACS reports grants from the NIH and UK National Institute for Health and Care Research (NIHR). AP received grants from the Wellcome Trust, the Bill & Melinda Gates Foundation, the NIH, and UK NIHR and payments from the Gates Foundation outside of the study. FB reports grants and personal fees from Gilead Sciences, outside the submitted work. IJ reports payments from Gilead Sciences, GESIDA, and ViiV Healthcare. MJG participated on advisory boards for Merck, Gilead, and ViiV. MBK has received grants and honoraria from ViiV Healthcare, AbbVie, and Gilead. LM reports grants from ANRS-MIE INSERM paid to her institution. RL received grants from Canadian Institutes of Health Research, Alberta Innovates, and the University of Calgary outside of the study. PR reports grants from Gilead Sciences, ViiV Healthcare, and Merck & Co. CAS and MvdV report grants and honoraria from Gilead Sciences, ViiV Healthcare, and MSD outside of the submitted work. BS reports financial support to his institution for travel grants from Gilead Sciences and ViiV healthcare, and for advisory boards from Gilead Sciences. GT received grants from Gilead Sciences and University College London and EU and national funds. AvS reports grants from the Dutch Ministry of Health, Welfare, and Sport and the European Centre for Disease Prevention and Control. LW received grants from ANRS-MIE. JMM has received consulting honoraria and research grants from Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Lysovant, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare, outside the submitted work. JMM has also received a personal 80:20 research grant from Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, during 2017–24. All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)